Analysts Set ICU Medical, Inc. (NASDAQ:ICUI) Target Price at $170.25

Shares of ICU Medical, Inc. (NASDAQ:ICUI) have received a consensus recommendation of “Moderate Buy” from the five research firms that are currently covering the firm, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $170.25.

A number of equities analysts have recently commented on the stock. KeyCorp lifted their price target on shares of ICU Medical from $147.00 to $198.00 and gave the stock an “overweight” rating in a report on Tuesday, October 15th. Raymond James upped their target price on ICU Medical from $158.00 to $190.00 and gave the company an “outperform” rating in a report on Thursday, September 12th. Needham & Company LLC restated a “hold” rating on shares of ICU Medical in a research report on Thursday, October 10th. StockNews.com raised shares of ICU Medical from a “hold” rating to a “buy” rating in a research report on Thursday, September 12th. Finally, Jefferies Financial Group began coverage on ICU Medical in a research report on Monday, October 14th. They issued a “hold” rating and a $183.00 price objective for the company.

ICU Medical Stock Up 0.0 %

Shares of ICUI opened at $175.56 on Thursday. The firm has a 50 day simple moving average of $172.59 and a two-hundred day simple moving average of $134.88. The company has a market cap of $4.29 billion, a P/E ratio of -60.12 and a beta of 0.66. ICU Medical has a one year low of $78.28 and a one year high of $188.53. The company has a debt-to-equity ratio of 0.76, a current ratio of 2.41 and a quick ratio of 1.08.

ICU Medical (NASDAQ:ICUI) last issued its earnings results on Wednesday, August 7th. The medical instruments supplier reported $1.56 earnings per share for the quarter, beating analysts’ consensus estimates of $1.00 by $0.56. The firm had revenue of $596.50 million for the quarter, compared to analyst estimates of $556.64 million. ICU Medical had a negative net margin of 3.07% and a positive return on equity of 5.01%. The company’s quarterly revenue was up 8.6% on a year-over-year basis. During the same quarter last year, the business posted $1.58 earnings per share. Research analysts forecast that ICU Medical will post 3.81 EPS for the current fiscal year.

Insider Activity at ICU Medical

In other ICU Medical news, VP Virginia Ruth Sanzone sold 2,050 shares of the firm’s stock in a transaction on Thursday, August 8th. The stock was sold at an average price of $144.11, for a total transaction of $295,425.50. Following the transaction, the vice president now directly owns 4,482 shares in the company, valued at approximately $645,901.02. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, VP Virginia Ruth Sanzone sold 2,050 shares of ICU Medical stock in a transaction on Thursday, August 8th. The stock was sold at an average price of $144.11, for a total transaction of $295,425.50. Following the sale, the vice president now directly owns 4,482 shares in the company, valued at approximately $645,901.02. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Vivek Jain sold 12,000 shares of the firm’s stock in a transaction on Friday, August 16th. The shares were sold at an average price of $156.04, for a total value of $1,872,480.00. Following the sale, the chief executive officer now directly owns 104,593 shares of the company’s stock, valued at approximately $16,320,691.72. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 40,552 shares of company stock valued at $6,679,322. 6.70% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. lifted its holdings in shares of ICU Medical by 14.8% in the 4th quarter. Vanguard Group Inc. now owns 2,440,729 shares of the medical instruments supplier’s stock worth $243,438,000 after acquiring an additional 315,103 shares during the last quarter. Silvercrest Asset Management Group LLC lifted its holdings in shares of ICU Medical by 109.4% during the first quarter. Silvercrest Asset Management Group LLC now owns 278,436 shares of the medical instruments supplier’s stock valued at $29,882,000 after purchasing an additional 145,485 shares in the last quarter. Mesirow Institutional Investment Management Inc. bought a new position in ICU Medical in the first quarter worth approximately $15,425,000. Victory Capital Management Inc. raised its holdings in ICU Medical by 2,966.3% in the 2nd quarter. Victory Capital Management Inc. now owns 141,848 shares of the medical instruments supplier’s stock worth $16,844,000 after purchasing an additional 137,222 shares during the period. Finally, Millennium Management LLC lifted its position in shares of ICU Medical by 327.8% during the 2nd quarter. Millennium Management LLC now owns 136,070 shares of the medical instruments supplier’s stock valued at $16,158,000 after buying an additional 104,264 shares in the last quarter. 96.10% of the stock is owned by institutional investors.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.